$ICCRW
iCoreConnect Inc. Stock $iccrw

$iccrw Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000147793221008377 Filed on November 15, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q4
Revenue	$1.906M	$1.365M	$615.6K
YoY Change	209.63%	157.57%	201.76%
Cost Of Revenue	$651.7K	$420.9K	$305.8K
YoY Change	113.09%	53.62%	427.31%
Gross Profit	$1.254M	$944.2K	$309.8K
YoY Change	304.95%	268.83%	112.16%
Gross Profit Margin	65.81%	69.17%	50.32%
Selling, General & Admin	$2.030M	$1.343M	$1.022M
YoY Change	98.63%	79.96%	-9.07%
% of Gross Profit	161.84%	142.19%	329.95%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$576.9K	$383.3K	$228.2K
YoY Change	152.78%	67.36%	19.49%
% of Gross Profit	45.99%	40.59%	73.68%
Operating Expenses	$2.606M	$1.693M	$1.251M
YoY Change	108.34%	73.69%	-4.86%
Operating Profit	-$1.352M	-$749.3K	-$941.3K
YoY Change	43.64%	4.21%	-19.48%
Interest Expense	-$143.0K	$97.55K	-$90.82K
YoY Change	57.47%	23.48%	183.81%
% of Operating Profit
Other Income/Expense, Net	-$297.2K	-$356.5K	-$60.73K
YoY Change	389.35%	548.13%	-5.11%
Pretax Income	-$1.462M	-$1.106M	-$1.080M
YoY Change	35.37%	42.86%	49.62%
Income Tax
% Of Pretax Income
Net Earnings	-$1.462M	-$1.106M	-$1.080M
YoY Change	35.37%	42.86%	49.62%
Net Earnings / Revenue	-76.72%	-81.0%	-175.48%
Basic Earnings Per Share
Diluted Earnings Per Share	-$8.387K	-$7.118K	-$12.34K
COMMON SHARES
Basic Shares Outstanding	159.2M shares	151.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$71.81K	$699.2K	$7.620K
YoY Change	842.39%	819.97%	-98.29%
Cash & Equivalents	$71.81K	$699.2K	$7.619K
Short-Term Investments
Other Short-Term Assets	$312.3K	$181.9K	$20.10K
YoY Change	1453.68%	506.4%	151.25%
Inventory
Prepaid Expenses
Receivables	$629.0K	$484.1K	$126.5K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.013M	$1.365M	$154.2K
YoY Change	557.06%	501.39%	-72.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$92.56K	$50.60K	$2.405K
YoY Change	3748.73%	-54.0%	-95.92%
Goodwill	$1.485M	$3.074M	$491.4K
YoY Change	202.21%		35.97%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$5.617M	$6.040M	$2.536M
YoY Change	121.46%	155.61%	28.89%
TOTAL ASSETS
Total Short-Term Assets	$1.013M	$1.365M	$154.2K
Total Long-Term Assets	$5.617M	$6.040M	$2.536M
Total Assets	$6.630M	$7.405M	$2.691M
YoY Change	146.42%	185.92%	6.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.642M	$1.244M
YoY Change		24.65%
Accrued Expenses	$66.74K	$58.50K	$89.09K
YoY Change	-25.09%	53.95%	61.98%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.325M	$1.198M	$1.429M
YoY Change	62.7%	-6.81%	62.41%
Total Short-Term Liabilities	$4.054M	$2.511M	$3.185M
YoY Change	27.28%	7.87%	64.52%
LONG-TERM LIABILITIES
Long-Term Debt	$1.538M	$2.750M	$0.00
YoY Change		2031.53%	-100.0%
Other Long-Term Liabilities	$32.32K	$52.66K	$134.4K
YoY Change	-75.96%	-65.36%	24.46%
Total Long-Term Liabilities	$1.571M	$2.802M	$134.4K
YoY Change	1068.56%	897.27%	11.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.054M	$2.511M	$3.185M
Total Long-Term Liabilities	$1.571M	$2.802M	$134.4K
Total Liabilities	$5.625M	$5.314M	$3.320M
YoY Change	69.45%	103.66%	61.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$82.80M	-$81.33M	-$77.83M
YoY Change	6.38%
Common Stock	$167.5K	$159.2K	$90.08K
YoY Change	85.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.005M	$2.092M	-$628.9K
YoY Change
Total Liabilities & Shareholders Equity	$6.630M	$7.405M	$2.691M
YoY Change	146.42%	185.92%	6.69%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q4
OPERATING ACTIVITIES
Net Income	-$1.462M	-$1.106M	-$1.080M
YoY Change	35.37%	42.86%	49.62%
Depreciation, Depletion And Amortization	$576.9K	$383.3K	$228.2K
YoY Change	152.78%	67.36%	19.49%
Cash From Operating Activities	-$968.3K	-$891.6K	-$128.5K
YoY Change	653.59%	96.39%	-26.58%
INVESTING ACTIVITIES
Capital Expenditures	$1.742M	-$1.434M	-$108.0K
YoY Change	-1713.4%	1056.67%	-13.6%
Acquisitions
YoY Change
Other Investing Activities	-$1.868M		$100.00
YoY Change	-1868040.0%
Cash From Investing Activities	-$125.5K	-$1.434M	-$107.9K
YoY Change	16.27%	1056.67%	-13.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	466.4K	2.179M	168.0K
YoY Change	177.59%	239.41%	-76.47%
NET CHANGE
Cash From Operating Activities	-968.3K	-891.6K	-128.5K
Cash From Investing Activities	-125.5K	-1.434M	-107.9K
Cash From Financing Activities	466.4K	2.179M	168.0K
Net Change In Cash	-627.4K	-146.9K	-68.38K
YoY Change	817.48%	-329.47%	-116.52%
FREE CASH FLOW
Cash From Operating Activities	-$968.3K	-$891.6K	-$128.5K
Capital Expenditures	$1.742M	-$1.434M	-$108.0K
Free Cash Flow	-$2.711M	$542.7K	-$20.49K
YoY Change	13129.67%	-264.44%	-59.02%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	159205016	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	699175	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7619	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	484062	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	126472	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	181918	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	154194	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50602	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2405	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20103	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	1365155	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	90819	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	150477	USD
CY2021Q3	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	668745	USD
CY2020Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	768907	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	399997	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	753794	USD
CY2021Q3	us-gaap	Finite Lived Customer Lists Gross FiniteLivedCustomerListsGross	1756131	USD
CY2020Q4	us-gaap	Finite Lived Customer Lists Gross FiniteLivedCustomerListsGross	369524	USD
CY2021Q3	us-gaap	Goodwill Goodwill	3073886	USD
CY2020Q4	us-gaap	Goodwill Goodwill	491376	USD
CY2021Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	6040180	USD
CY2020Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	2536483	USD
CY2021Q3	us-gaap	Assets Assets	7405335	USD
CY2020Q4	us-gaap	Assets Assets	2690677	USD
CY2021Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1243991	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1664125	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	58503	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	89088	USD
CY2021Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	1198373	USD
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1429207	USD
CY2021Q3	us-gaap	Deferred Revenue Leases Current DeferredRevenueLeasesCurrent	10409	USD
CY2020Q4	us-gaap	Deferred Revenue Leases Current DeferredRevenueLeasesCurrent	2775	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2511276	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3185195	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	32316	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	61389	USD
CY2021Q3	us-gaap	Deferred Revenue And Credits Noncurrent DeferredRevenueAndCreditsNoncurrent	20344	USD
CY2020Q4	us-gaap	Deferred Revenue And Credits Noncurrent DeferredRevenueAndCreditsNoncurrent	73033	USD
CY2021Q3	us-gaap	Notes Payable Current NotesPayableCurrent	2749682	USD
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2021Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2802342	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	134422	USD
CY2021Q3	us-gaap	Liabilities Liabilities	5313618	USD
CY2020Q4	us-gaap	Liabilities Liabilities	3319617	USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	159205016	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	90081336	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	159205	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	90081	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	83265503	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	77112060	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-81332991	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-77831081	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	2091717	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-628940	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7405335	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2690677	USD
CY2021Q3	us-gaap	Revenues Revenues	1365112	USD
CY2020Q3	us-gaap	Revenues Revenues	530000	USD
	us-gaap	Revenues Revenues	3050488	USD
	us-gaap	Revenues Revenues	1508000	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	420915	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	274000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	928675	USD
CY2021Q3	us-gaap	Gross Profit GrossProfit	944197	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	256000	USD
	us-gaap	Gross Profit GrossProfit	2121813	USD
	us-gaap	Gross Profit GrossProfit	805000	USD
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1342531	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	746000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3202789	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2425000	USD
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	350957	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	703000	USD
CY2020Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	229000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	854368	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	677000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	1693488	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	975000	USD
	us-gaap	Operating Expenses OperatingExpenses	4057157	USD
	us-gaap	Operating Expenses OperatingExpenses	3102000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-749291	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-719000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1935344	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2297000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	97551	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	79000	USD
	us-gaap	Interest Expense InterestExpense	357873	USD
	us-gaap	Interest Expense InterestExpense	148000	USD
CY2021Q3	us-gaap	Other Income OtherIncome	26732	USD
CY2020Q3	us-gaap	Other Income OtherIncome	0	USD
	us-gaap	Other Income OtherIncome	304672	USD
	us-gaap	Other Income OtherIncome	10000	USD
CY2021Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-232189	USD
CY2020Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2021Q3	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	0	USD
CY2020Q3	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	24000	USD
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	0	USD
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	24000	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-356472	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-55000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1566567	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-114000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1105763	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-774000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3501911	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2411000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2021Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	155351644	shares
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	75923838	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	137519808	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	72776256	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	465000	USD
CY2020Q1	icct	Stock Issued For Cash And Conversion Of Notes Payable Amount StockIssuedForCashAndConversionOfNotesPayableAmount	590000	USD
CY2020Q1	icct	Stock Issued For Services StockIssuedForServices	0	USD
CY2020Q1	icct	Stock Compensation Expense Amount StockCompensationExpenseAmount	95000	USD
CY2020Q1	icct	Stock Issued For Asset Acquisition Of Trinit Amount StockIssuedForAssetAcquisitionOfTrinitAmount	183000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-780000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	553000	USD
CY2020Q2	icct	Stock Issued For Cash Amount StockIssuedForCashAmount	25000	USD
CY2020Q2	icct	Stock Issued For Conversion Of Note Payable Amount StockIssuedForConversionOfNotePayableAmount	8000	USD
CY2020Q2	icct	Stock Compensation Expense Amount StockCompensationExpenseAmount	225000	USD
CY2020Q2	icct	Stock Issued For Conversion Of Accounts Payable Amount StockIssuedForConversionOfAccountsPayableAmount	250000	USD
CY2020Q2	icct	Stock Issued For Stock Option Exercises Amount StockIssuedForStockOptionExercisesAmount	1000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-628940	USD
CY2021Q1	icct	Stock Issued For Cash Amount StockIssuedForCashAmount	1417313	USD
CY2021Q1	icct	Stock Issued For Conversion Of Fees For Services Payable Amount StockIssuedForConversionOfFeesForServicesPayableAmount	481923	USD
CY2021Q1	icct	Stock Compensation Expense Amount StockCompensationExpenseAmount	118796	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-812914	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	576178	USD
CY2021Q2	icct	Stock Issued For Cash Amount StockIssuedForCashAmount	1503500	USD
CY2021Q2	icct	Stock Compensation Expense Amount StockCompensationExpenseAmount	68945	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-857000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	205000	USD
CY2020Q3	icct	Stock Issued For Cash Amount StockIssuedForCashAmount	382000	USD
CY2020Q3	icct	Stock Issued For Conversion Of Convertible Notes Payable Amount StockIssuedForConversionOfConvertibleNotesPayableAmount	118000	USD
CY2020Q3	icct	Stock Compensation Expense StockCompensationExpense	48000	USD
CY2020Q3	icct	Stock Issued As Origination Fee In Convertible Debt Agreement Amount StockIssuedAsOriginationFeeInConvertibleDebtAgreementAmount	2000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-774000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	-19000	USD
CY2021Q2	icct	Stock Issued For Convertible Debt Amount StockIssuedForConvertibleDebtAmount	1283906	USD
CY2021Q2	icct	Stock Issued For Asset Acquisition Of Advantech Amount StockIssuedForAssetAcquisitionOfAdvantechAmount	500000	USD
CY2021Q2	icct	Stock Issued For Asset Acquisition Of Bcs Amount StockIssuedForAssetAcquisitionOfBcsAmount	250	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1583233	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	2349546	USD
CY2021Q3	icct	Stock Issued For Cash Amount StockIssuedForCashAmount	100000	USD
CY2021Q3	icct	Stock Compensation Expense Amount StockCompensationExpenseAmount	15744	USD
CY2021Q3	icct	Stock Issued As Origination Fee In Convertible Debt Agreement Amount StockIssuedAsOriginationFeeInConvertibleDebtAgreementAmount	232190	USD
CY2021Q3	icct	Stock Issued For Asset Acquisition Of Spectrum Technology Solutions Amount StockIssuedForAssetAcquisitionOfSpectrumTechnologySolutionsAmount	500000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1105763	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	2091717	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3501911	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2411000	USD
	us-gaap	Depreciation Depreciation	2832	USD
	us-gaap	Depreciation Depreciation	6000	USD
	us-gaap	Deferred Sales Inducements Amortization Expense DeferredSalesInducementsAmortizationExpense	851537	USD
	us-gaap	Deferred Sales Inducements Amortization Expense DeferredSalesInducementsAmortizationExpense	671000	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1513366	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
	icct	Change In Allowance For Doubtful Accounts ChangeInAllowanceForDoubtfulAccounts	0	USD
	icct	Change In Allowance For Doubtful Accounts ChangeInAllowanceForDoubtfulAccounts	60000	USD
	icct	Gain On Cancellation Of Liabilities GainOnCancellationOfLiabilities	-331404	USD
	icct	Gain On Cancellation Of Liabilities GainOnCancellationOfLiabilities	-24000	USD
	us-gaap	Dividends Sharebased Compensation Stock DividendsSharebasedCompensationStock	113657	USD
	us-gaap	Dividends Sharebased Compensation Stock DividendsSharebasedCompensationStock	368000	USD
	icct	Non Cash Interest Expense NonCashInterestExpense	102645	USD
	icct	Non Cash Interest Expense NonCashInterestExpense	43000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-322368	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-80000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-161815	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-16000	USD
	icct	Right Of Use Asset Net Of Lease Liability RightOfUseAssetNetOfLeaseLiability	-59658	USD
	icct	Right Of Use Asset Net Of Lease Liability RightOfUseAssetNetOfLeaseLiability	-2000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-89788	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	268000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-45055	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-25000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1927962	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1142000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	3200022	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	375000	USD
	icct	Additions To Capitalized Software AdditionsToCapitalizedSoftware	-183863	USD
	icct	Additions To Capitalized Software AdditionsToCapitalizedSoftware	-435000	USD
	icct	Purchases Of Capital Assets PurchasesOfCapitalAssets	-9154	USD
	icct	Purchases Of Capital Assets PurchasesOfCapitalAssets	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3393039	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-810000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	3300881	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	676000	USD
	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-875887	USD
	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-71000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3587563	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	977000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6012557	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1583000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	691556	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-369000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7619	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	445000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	699175	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	76531	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	77000	USD
	us-gaap	Interest Paid Net InterestPaidNet	233465	USD
	us-gaap	Interest Paid Net InterestPaidNet	74000	USD
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	183000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76000	USD
CY2021Q3	icct	Working Capital Deficit WorkingCapitalDeficit	-1146122	USD
	icct	Stock Issued For Acquisition Of Technology StockIssuedForAcquisitionOfTechnology	0	USD
	icct	Stock Issued For Acquisition Of Technology StockIssuedForAcquisitionOfTechnology	0	USD
	icct	Stock Issued For Conversion Of Convertible Notes Payable StockIssuedForConversionOfConvertibleNotesPayable	0	USD
	icct	Stock Issued For Conversion Of Convertible Notes Payable StockIssuedForConversionOfConvertibleNotesPayable	146000	USD
	icct	Stock Issued For Conversion Of Notes Payable StockIssuedForConversionOfNotesPayable	0	USD
	icct	Stock Issued For Conversion Of Notes Payable StockIssuedForConversionOfNotesPayable	0	USD
	icct	Stock Issued For Conversion Of Accounts Payable StockIssuedForConversionOfAccountsPayable	-7266	USD
	icct	Stock Issued For Conversion Of Accounts Payable StockIssuedForConversionOfAccountsPayable	250000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. NATURE OF OPERATIONS </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">iCoreConnect Inc., (the “Company”), a Nevada Corporation, develops and markets secure cloud-based HIPAA compliant software as a service (SaaS) focused on compliance, workflow/productivity, and electronic health records systems. The Company also offers both managed IT (MSP) and managed software as a service (MSaaS) with recurring revenue subscriptions. Our core services technology can be adopted to other vertical markets that require a high degree of secure data communication, such as the legal, financial and education sectors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Software as a Service (SaaS) Offerings</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company currently markets secure HIPAA compliant cloud-based software as a service (SaaS) offering under the names of iCoreExchange, iCoreCodeGenius, iCoreSecure, iCoreMD, iCoreDental, iCoreMobile, iCoreHuddle, iCoreRx, iCorePDMP, iCoreEPCS, iCoreVerify. iCoreCloud and iCorePay. The Company’s software is sold under annual recurring revenue subscriptions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>iCoreExchange</strong> – iCoreExchange offers hospitals, physician practices, dental practices, and other healthcare professionals the extensive functionality needed to securely transfer patient health information to anyone, anywhere and at any time. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">iCoreExchange provides a secure, HIPAA compliant email solution using the Direct Protocol that allows doctors to send and receive secure email with attachments to and from other healthcare professionals in the network or outside the network. iCoreExchange also provides a secure email mechanism to communicate with users outside the exchange e.g., patients and referrals. Users have the ability to build a community, access other communities and increase referrals and collaboration. Users can email standard office documents, JPEG, PDF as well as files with discrete data, Consolidated Clinical Document Architecture (“CCDA”), which can then be imported and accessed on most Electronic Health Record (EHR) and Practice Management systems in a HIPAA compliant manner.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Health Insurance Portability and Accountability Act of 1996 (HIPAA) requires providers and healthcare professionals to transmit encrypted personal health information via electronic means. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>iCoreCodeGenius</strong> – is Coding Software that provides the coding standards for the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD), a medical classification list published by the World Health Organization (WHO). It contains codes for diseases, signs and symptoms, abnormal findings, complaints, social circumstances and external causes of injury and diseases.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Users can document any medical condition in 60 seconds or less. It includes a full ICD-10 code lookup and guidance, automatic prompting of comorbidities and Hierarchical Condition Category’s (HCC) appropriate reimbursement with a high degree of accuracy, and the ability to reduce or eliminate queries and denials.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>iCoreSecure </strong>–We used our expertise and development capabilities from our HIPAA compliant iCoreExchange and developed iCoreSecure, an encrypted email solution for anyone that needs encrypted email to protect personal and financial data. iCoreSecure solves privacy concerns in the insurance, real estate, financial and many other industry sectors that have a need for secure encrypted email.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>iCoreMD</strong> and <strong>iCoreDental -- iCoreMD and iCoreDental </strong>are complete EHR/Practice Management software solution platforms created for the medical and dental communities in response to feedback from doctors and dentists telling us they wanted a cloud-based software that was more flexible than the current medical and dental platforms in the marketplace. The software includes patient demographics, scheduling, billing, electronic medical records, electronic claims, e-prescriptions, labs, merchant services, and patient reminders along with a complete suite of standard reporting capabilities and data analytics to help run a medical or dental practice.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our cloud-based software was certified in November 2015 by the Office of the National Coordinator for Health Information Technology (ONC), certificate number 150120r0.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>iCoreMobile -- </strong>iCoreMobile is our third complete EHR software platform. It was designed and built specifically for mobile medical and dental care centers. In addition to the features included in iCoreMD and iCoreDental, iCoreMobile also includes workflow optimizations and process enhancements to cater to providers in mobile settings. The software utilizes fully customizable patient intake forms to improve workflow. The software ensures that once a patient’s C-CDA import has been accepted, it is immediately available on all mobile workstations. The enhanced reporting system and metrics provides the main office with extensive data analytics of the mobile unit. The customizable nature of the reporting system allows mobile operators to compare the efficiency of their units.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>iCoreHuddle – </strong>iCoreHuddle is a powerful analytical tool that instantly reveals the revenue potential of each patient. The service connects to most popular practice management and EHR systems to optimize revenue realization. It provides the practice with a dashboard containing various metrics, analytics, and Key Performance Indicators (“KPIs”). iCoreHuddle provides a daily view of patient schedules, including their outstanding balances, uncompleted treatment plans, recall information, procedure information and the amount of remaining insurance benefits. The software also provides one-click access to each patient’s insurance eligibility, including a detailed benefits and deductibles report. This tool aims to increase the workflow efficiency of the dentist’s practice by reducing the number of required lookups and clicks for each patient. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>iCoreRx – iCoreRx </strong>is a HIPAA compliant electronic ePrescription software that integrates with popular practice management and EHR systems. This module saves time by selecting exact medications at available doses with built-in support from a drug directory and provides full support for EPCS (electronic prescribed controlled substances). It protects both the patient and provider by viewing the patient’s complete medication history. It also speeds up the process by allowing the doctor to create a “favorites” list for commonly used medication sets. iCorePDMP is an add-on for iCoreRx that seamlessly integrates with state databases to automate prescription drug monitoring. Providers in many states are required to check the patient’s Prescription Drug Monitoring Program (PDMP / PMP) history before prescribing controlled substances. This service provides a one-click real-time access to the state databases without the need to manually enter data and provides access to PDMP data, including a patient’s health history. This tool also generates patient risk scores and an interactive visualization of usage patterns to help the prescriber identify potential risk factors. The prescriber can then use this report to make decisions on objective insight into potential drug misuse or abuse which will ultimately lead to improved patient safety and better patient outcomes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>iCoreVerify –</strong> Allows practices to very patient insurance verification benefits automatically in advance of the patients visit. Response from payer database typically takes less than 1 second after clicking our Real-Time Benefit Check (RTBC) button Real-time technology checks patient’s benefits availability directly from the payer‘s database with no need to speak to a representative. Results indicate remaining available benefits substantially reduces required phone calls and labor hours integrates with popular practice management software.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>IT Managed Services - </strong>The trend in IT Services companies for over a decade has been to model towards “Managed Service Provider (MSP)” and Managed Software as a Services (MSaaS) models with monthly recurring revenue (MRR). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The MSP approach, by using preventative measures, keeps computers and networks up and running while data is accessible and safeguarded. Installation of critical patches and updates to virus protection are automated. Systems are monitored and backed up in real-time. They are fixed or upgraded before they cause a service disruption. A Unified Threat Management solution is deployed to protect against virus, malware, SPAM, phishing and ransomware attacks. All support is delivered at a predictable monthly cost.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Going forward, by leveraging managed services with our expertise in cloud computing, our customers can easily scale their business without extensive capital investment or disruption in services. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is competitively positioned to address the growing need for managed services:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our current and future customers need managed IT services, along with cloud computing, storage and HIPAA compliant backup and encryption.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Managed service providers that can support the migration to cloud computing are in high demand.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The decision makers for our current technology and those for managed services are, in many cases, the same person or group of people.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our management team has decades of experience operating successful IT companies.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The MSP revenue model matches our SaaS, MSaaS and MRR models.</p></td></tr></tbody></table>
CY2021Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
CY2021Q3	us-gaap	Goodwill Gross GoodwillGross	3074000.000	USD
	icct	Revenue Description RevenueDescription	The Company’s secondary source of revenue is professional services and other revenue related to customer onboarding, IT services and equipment sales that often precede a subscription service offering purchased by the customer. Eighty-eight percent of our revenue is subscription based with the remainder being professional services and other IT related revenue. The geographic concentration of our revenue is 100% in North America
	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for derivative instruments in accordance with ASC 815, which requires additional disclosures about the Company’s objectives and strategies for using derivative instruments, how the derivative instruments and related hedged items are accounted for, and how the derivative instruments and related hedging items affect the financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risk. Terms of convertible debt and preferred stock instruments are reviewed to determine whether or not they contain embedded derivative instruments that are required under ASC 815 to be accounted for separately from the host contract and recorded on the balance sheet at fair value. The fair value of derivative liabilities, if any, is required to be revalued at each reporting date, with corresponding changes in fair value recorded in current period operating results.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Freestanding warrants issued by the Company in connection with the issuance or sale of debt and equity instruments are considered to be derivative instruments. Pursuant to ASC 815, an evaluation of specifically identified conditions is made to determine whether the fair value of warrants issued is required to be classified as equity or as a derivative liability.</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and to the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</p>
	icct	Total Revenue Percentage TotalRevenuePercentage	0.10	pure
	icct	Total Revenue Percentage TotalRevenuePercentage	0.10	pure
	us-gaap	Concentration Risk Benchmark Description ConcentrationRiskBenchmarkDescription	Overall, the company grew its accounts receivable approximately ending balance 283% for the nine months ending September 30, 2021 compared to the nine months ending September 30, 2020, compared to an over 102% growth in sales for the same period. Day’s sales outstanding was less than 30 days as of September 30, 2021
	icct	Going Concerntextblock GoingConcerntextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the nine-month period ended September 30, 2021, the Company generated an operating loss of $1,935,344. In addition, the Company has an accumulated deficit, total stockholders’ equity and net working capital deficit of $81,332,991, $2,091,717 and $1,146,122, respectively, on September 30, 2021. The Company’s activities were primarily financed through private placements of equity securities. The Company intends to raise additional capital through the issuance of debt and/or equity securities to fund its operations. The Company is reliant on future fundraising to finance operations in the near future. The financing may not be available on terms satisfactory to the Company, if at all. In light of these matters, there is substantial doubt that the Company will be able to continue as a going concern.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Currently, management intends to develop a vastly improved healthcare communications system and intends to develop alliances with strategic partners to generate revenues that will sustain the Company. While management believes in the viability of its strategy to increase revenues and in its ability to raise additional funds, there can be no assurances to that effect. Management’s ability to continue as a going concern is ultimately dependent upon its ability to continually increase the Company’s customer base and realize increased revenues from signed contracts. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p>
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1935344	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-81332991	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	2091717	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>3. NOTES PAYABLE AND DERIVATIVE LIABILITY</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Notes Payable</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued a note payable to a related party on December 31, 2018 with a principal amount of $714,000, bearing interest at a rate of 18% per annum, with monthly principal and accrued interest payments and with a balloon payment due by the maturity date of December 31, 2019. The balloon payment due on December 31, 2019 was not made and the Company issued, in exchange for the original note, a new note dated December 31, 2019 with a principal amount of $556,000, bearing interest at a rate of 18% per annum, with monthly principal and accrued interest payments and a balloon payment due by the maturity date of December 31, 2020.The amounts owing on the note as of December 31, 2019 were $556,000 of principal plus a nominal amount of accrued interest. As of December 31, 2020, $535,021 of principal was outstanding on this note payable. Subsequent to the end of fiscal 2020, the maturity on note payable to the related party was extended to a new 2-year term note payable bearing interest rate payable of 18% per annum with a maturity date of December 31, 2023. The note will pay monthly cash interest only in the first year (12 months) of note payable term. In the 2nd year, the note payable will be repaid with 12 monthly installment payments of interest and principal until fully repaid.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In April 2021, the Company signed a $150,000 convertible promissory note with a maturity date twelve months after issuance and received in exchange $150,000 from a finance company (the “Investor” or “Holder”). An Interest charge of 12% per annum shall accrue and be paid on the maturity date. The note is convertible into the Company’s Common Stock at fixed conversion price $0.10 per common share. The Company has right of prepayment. The note holder is limited to receive upon conversion no more than 4.99% of the issued and outstanding Common Stock at the time of conversion at any one time. The Company also issued to the Holder 780,000 restricted shares of the Company’s Common Stock and 2,600,000 cash Warrant Shares with a 5-year term. The exercise price per share of Common Stock under this Warrant is $0.20 per share for the first 1,300,000 Warrant Shares and $0.25 for the next 1,300,000 Warrant Shares.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In April 2021, the Company signed a $350,000 convertible promissory note with a maturity date twelve months after issuance and received in exchange $350,000 from the same finance company (the “Investor” or “Holder”). An Interest charge of 12% per annum shall accrue and be paid on the maturity date. The note is convertible into the Company’s Common Stock at a fixed conversion price of $0.10 per common share. The Company has right of prepayment. The note holder is limited to receive upon conversion no more than 4.99% of the issued and outstanding Common Stock at the time of conversion at any one time. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In April 2021, the Company signed a $500,000 convertible promissory note with a maturity date twelve months after issuance and received in exchange $500,000 from a second finance company (the “Investor” or “Holder”). An Interest charge of 12% per annum shall accrue and be paid on the maturity date. The note is convertible into the Company’s Common Stock at a fixed conversion price of $0.10 per common share. The Company has right of prepayment. The note holder is limited to receive upon conversion no more than 4.99% of the issued and outstanding Common Stock at the time of conversion at any one time. The company also issued to the Holder 788,000 restricted shares of the Company’s Common Stock and 2,600,000 cash Warrant Shares with a 5-year term. The exercise price per share of Common stock under this Warrant is $0.20 per share for the first 1,300,000 Warrant Shares and $0.25 for the next 1,300,000 Warrant Shares.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In April 2021, the Company signed a $250,000 convertible promissory note with a maturity date twelve months after issuance and received in exchange $250,000 from a third finance company (the “Investor” or “Holder”). An Interest charge of 12% per annum shall accrue and be paid on the maturity date. The note is convertible into the Company’s Common Stock at fixed conversion price $0.10 per common share. The Company has right of prepayment. The note holder is limited to receive upon conversion no more than 4.99% of the issued and outstanding Common Stock at the time of conversion at any one time. The Company also issued to the Holder 390,000 restricted shares of the Company’s Common Stock and 1,300,000 cash Warrant Shares with a 5-year term. The exercise price per share of Common stock under this Warrant is $0.20 per share for the first 650,000 Warrant Shares and $0.25 for the next 650,000 Warrant Shares.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In April 2021, the Company signed a $250,000 convertible promissory note with a maturity date twelve months after issuance and received in exchange $230,000 net of fees from a fourth finance company (the “Investor” or “Holder”). An Interest charge of 12% per annum shall accrue and be paid on the maturity date. The note is convertible into the Company’s Common Stock at fixed conversion price $0.10 per common share. The Company has right of prepayment. The note holder is limited to receive upon conversion no more than 4.99% of the issued and outstanding Common Stock at the time of conversion at any one time. The Company also issued to the Holder 390,000 restricted shares of the Company’s Common Stock and 1,300,000 cash Warrant Shares with a 5-year term. The exercise price per share of Common stock under this Warrant is $0.20 per share for the first 650,000 Warrant Shares and $0.25 for the next 650,000 Warrant Shares.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2021, the Company signed a $1,000,000 and $500,000 promissory note with a maturity date 24 months after issuance from the preliminary finance company in April 2021 (the “Investor” or “Holder”). An Interest charge of 15% per annum shall accrue and be paid on the maturity date. The Company also issued to the Holder 1,000,000 restricted shares of the Company’s Common Stock and 1,500,000 cash Warrant Shares with a 5-year term. The exercise price per share of Common stock under this Warrant is $0.25 per share.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Derivative Liability</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company entered into several agreements, which have been accounted for as derivatives. The Company has recorded a loss contingency associated with these agreements because it is both probable that a liability had been incurred and the amount of the loss can reasonably be estimated. The main factors that will affect the fair value of the derivative are the number of the Company’s shares outstanding post acquisition or post offering and the resulting market capitalization.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ASC Topic 815 (“ASC 815” requires that all derivative financial instruments be recorded on the balance sheet at fair value. Fair values for exchange traded securities and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgement and estimates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued warrants and has evaluated the terms and conditions of the conversion features contained in the warrants to determine whether they represent embedded or freestanding derivative instruments under the provisions of ASC 815. The Company determined that the conversion features contained in the warrants represent freestanding derivative instruments that meet the requirements for liability classification under ASC 815. As a result, the fair value of the derivative financial instruments in the warrants is reflected in the Company’s balance sheet as a liability. The fair value of the derivative financial instruments of the warrants was measured at the inception date of the warrants and each subsequent balance sheet date. Any changes in the fair value of the derivative financial instruments are recorded as non-operating, non-cash income, or expense at each balance sheet date. Additionally, the Company has issued convertible notes with variable conversion features resulting in a derivative liability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company valued the conversion features in its warrants and convertible notes using the Black-Scholes model.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Included in the September 30, 2021 and December 31, 2020 financial statements is a derivative liability in the amount of $715,223 and $0, respectively, to account for these transaction. It is revalued quarterly henceforth and adjusted as a gain or loss to the consolidated statements of operations depending on its value at that time.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong> </strong></p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> September 30, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> December 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Derivative Liability - Warrants</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt"><strong>Estimated number of underlying shares</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,600,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt"><strong>Estimated market price per share</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt"><strong>Exercise price per share</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td>$ </td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.20 to $0.25 </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt"><strong>Expected volatility</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">247</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt"><strong>Expected dividends</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt"><strong>Expected term (in years)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt"><strong>Derivative liability</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">715,223</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Derivative Liability - Convertible Notes</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt"><strong>Estimated number of underlying shares</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,730,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt"><strong>Estimated market price per share</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.13</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt"><strong>Exercise price per share</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.10</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt"><strong>Expected volatility</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">247</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt"><strong>Expected dividends</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt"><strong>Expected term (in years)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 11.25pt"><strong>Derivative liability</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">349,488</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Included in the Statements of Operations for the six months ended September 30, 2021 and September 30, 2020 is a loss of $1,513,366 and $0 in change of fair value of derivative in non-cash charges pertaining to the derivative liability as it pertains to the gain (loss) on derivative liability and debt discount, respectively.</p>
	icct	Number Of Options Warrants Outstanding Beginning NumberOfOptionsWarrantsOutstandingBeginning	1405000	shares
	icct	Weighted Average Exercise Price Beginning WeightedAverageExercisePriceBeginning	0.24
	icct	Weighted Average Remaining Contractual Term In Years Beginning WeightedAverageRemainingContractualTermInYearsBeginning	P7Y8M12D
	icct	Aggregate Intrinsic Value Beginning AggregateIntrinsicValueBeginning	0	USD
	icct	Number Of Options Warrants Outstanding Granted NumberOfOptionsWarrantsOutstandingGranted	2880000	shares
	icct	Weighted Average Exercise Price Granted WeightedAverageExercisePriceGranted	0.13
	icct	Weighted Average Remaining Contractual Term In Years Granted WeightedAverageRemainingContractualTermInYearsGranted	P10Y
	icct	Aggregate Intrinsic Value Ending AggregateIntrinsicValueEnding	0	USD
	icct	Number Of Options Warrants Outstanding Exercised NumberOfOptionsWarrantsOutstandingExercised	-10000	shares
	icct	Weighted Average Exercise Price Exercised WeightedAverageExercisePriceExercised	0.15
	icct	Weighted Average Remaining Contractual Term In Years Exercised WeightedAverageRemainingContractualTermInYearsExercised	P0Y
	icct	Number Of Options Warrants Outstanding Ending NumberOfOptionsWarrantsOutstandingEnding	4275000	shares
	icct	Weighted Average Exercise Price Exercisable WeightedAverageExercisePriceExercisable	0.15
	icct	Weighted Average Remaining Contractual Term In Years Ending WeightedAverageRemainingContractualTermInYearsEnding	P9Y
	icct	Number Of Options Outstanding Exercisable Ending NumberOfOptionsOutstandingExercisableEnding	1395000	shares
	icct	Weighted Average Exercise Price Ending WeightedAverageExercisePriceEnding	0.24
	icct	Weighted Average Remaining Contractual Term In Years Exercisable Ending WeightedAverageRemainingContractualTermInYearsExercisableEnding	P6Y10M24D
	icct	Weighted Average Grant Date Fair Value Nonvested Beginning WeightedAverageGrantDateFairValueNonvestedBeginning	0
	icct	Weighted Average Remaining Years To Vest Nonvested Begining WeightedAverageRemainingYearsToVestNonvestedBegining	P0Y
	icct	Number Of Options Nonvested Granted NumberOfOptionsNonvestedGranted	2800000	shares
	icct	Weighted Average Remaining Years To Vest Nonvested Granted WeightedAverageRemainingYearsToVestNonvestedGranted	P3Y
	icct	Weighted Average Grant Date Fair Value Nonvested Vested WeightedAverageGrantDateFairValueNonvestedVested	0
	icct	Number Of Options Nonvested Ending NumberOfOptionsNonvestedEnding	2800000	shares
	icct	Weighted Average Grant Date Fair Value Nonvested Ending WeightedAverageGrantDateFairValueNonvestedEnding	0
	icct	Weighted Average Remaining Years To Vest Nonvested Ending WeightedAverageRemainingYearsToVestNonvestedEnding	P3Y
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	10600000	shares
	icct	Summary Of Lease Commitmentstabletextblock SummaryOfLeaseCommitmentstabletextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="15" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>iCoreConnect Lease Commitments</strong></p></td></tr><tr style="height:15px"><td colspan="15" style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>as of September 30, 2021</strong></p></td></tr><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Less than 1 year</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>1-3 years</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>3-5 years</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td></tr><tr style="height:15px"><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="ffcell" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="ffcell" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td class="ffcell" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">246,672</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">770,010</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">609,536</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,626,218</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2021Q3	us-gaap	Other Commitment OtherCommitment	1626218	USD
CY2021Q3	icct	Disposition Obligation DispositionObligation	863274	USD
CY2021Q3	icct	Tendering Payment TenderingPayment	28577	USD
	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	4046617	shares
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1350000	USD
CY2021Q3	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	2000000	USD

Files In Submission

Name	View Source	Status
0001477932-21-008377-index-headers.html	Edgar Link	pending
0001477932-21-008377-index.html	Edgar Link	pending
0001477932-21-008377.txt	Edgar Link	pending
0001477932-21-008377-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
icct-20210930.xsd	Edgar Link	pending
icct-20210930_cal.xml	Edgar Link	unprocessable
icct-20210930_def.xml	Edgar Link	unprocessable
icct-20210930_lab.xml	Edgar Link	unprocessable
icct-20210930_pre.xml	Edgar Link	unprocessable
icct_10q.htm	Edgar Link	pending
icct_10q_htm.xml	Edgar Link	completed
icct_ex311.htm	Edgar Link	pending
icct_ex312.htm	Edgar Link	pending
icct_ex321.htm	Edgar Link	pending
icct_ex322.htm	Edgar Link	pending
icct_ex56.htm	Edgar Link	pending
icct_ex56img63.jpg	Edgar Link	pending
icct_ex56img64.jpg	Edgar Link	pending
icct_ex57.htm	Edgar Link	pending
icct_ex57img192.jpg	Edgar Link	pending
icct_ex57img193.jpg	Edgar Link	pending
icct_ex57img194.jpg	Edgar Link	pending
icct_ex57img195.jpg	Edgar Link	pending
icct_ex57img196.jpg	Edgar Link	pending
icct_ex57img197.jpg	Edgar Link	pending
icct_ex57img198.jpg	Edgar Link	pending
icct_ex57img199.jpg	Edgar Link	pending
icct_ex57img200.jpg	Edgar Link	pending
icct_ex57img201.jpg	Edgar Link	pending
icct_ex57img202.jpg	Edgar Link	pending
icct_ex57img203.jpg	Edgar Link	pending
icct_ex57img204.jpg	Edgar Link	pending
icct_ex57img205.jpg	Edgar Link	pending
icct_ex57img206.jpg	Edgar Link	pending
icct_ex57img207.jpg	Edgar Link	pending
icct_ex57img208.jpg	Edgar Link	pending
icct_ex57img209.jpg	Edgar Link	pending
icct_ex57img210.jpg	Edgar Link	pending
icct_ex57img211.jpg	Edgar Link	pending
icct_ex57img212.jpg	Edgar Link	pending
icct_ex57img213.jpg	Edgar Link	pending
icct_ex57img214.jpg	Edgar Link	pending
icct_ex57img215.jpg	Edgar Link	pending
icct_ex57img216.jpg	Edgar Link	pending
icct_ex57img217.jpg	Edgar Link	pending
icct_ex57img218.jpg	Edgar Link	pending
icct_ex57img219.jpg	Edgar Link	pending
icct_ex57img222.jpg	Edgar Link	pending
icct_ex57img223.jpg	Edgar Link	pending
icct_ex57img224.jpg	Edgar Link	pending
icct_ex57img225.jpg	Edgar Link	pending
icct_ex57img226.jpg	Edgar Link	pending
icct_ex57img227.jpg	Edgar Link	pending
icct_ex57img228.jpg	Edgar Link	pending
icct_ex57img229.jpg	Edgar Link	pending
icct_ex57img230.jpg	Edgar Link	pending
icct_ex57img231.jpg	Edgar Link	pending
icct_ex57img232.jpg	Edgar Link	pending
icct_ex57img233.jpg	Edgar Link	pending
icct_ex57img234.jpg	Edgar Link	pending
icct_ex57img235.jpg	Edgar Link	pending
icct_ex57img236.jpg	Edgar Link	pending
icct_ex57img237.jpg	Edgar Link	pending
icct_ex57img238.jpg	Edgar Link	pending
icct_ex57img239.jpg	Edgar Link	pending
icct_ex57img240.jpg	Edgar Link	pending
icct_ex57img241.jpg	Edgar Link	pending
icct_ex57img242.jpg	Edgar Link	pending
icct_ex57img243.jpg	Edgar Link	pending
icct_ex57img244.jpg	Edgar Link	pending
icct_ex57img245.jpg	Edgar Link	pending
icct_ex57img246.jpg	Edgar Link	pending
icct_ex57img247.jpg	Edgar Link	pending
icct_ex57img63.jpg	Edgar Link	pending
icct_ex57img64.jpg	Edgar Link	pending
icct_ex57img65.jpg	Edgar Link	pending
icct_ex57img66.jpg	Edgar Link	pending
icct_ex57img67.jpg	Edgar Link	pending
icct_ex57img68.jpg	Edgar Link	pending
icct_ex57img69.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ICCRW
iCoreConnect Inc. Stock $iccrw

2021 Q4 Form 10-Q Financial Statement

#000147793221008377 Filed on November 15, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICCRW iCoreConnect Inc. Stock $iccrw

2021 Q4 Form 10-Q Financial Statement

#000147793221008377 Filed on November 15, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ICCRW
iCoreConnect Inc. Stock $iccrw